We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 465.00
Bid: 460.00
Ask: 470.00
Change: -5.00 (-1.06%)
Spread: 10.00 (2.174%)
Open: 470.00
High: 470.00
Low: 465.00
Prev. Close: 470.00
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Supply and Distribution Agree

23 Jun 2008 07:00

RNS Number : 2319X
Tristel PLC
23 June 2008
 



 

TRISTEL plc

Supply and distribution agreement with Bio-Cide International, Inc.United States, and representation in the Biocidal Products Directive

Tristel plc ("Tristel" or the "Group"), the AIM listed provider of infection and contamination control products, announces that it has entered into a new 20 year supply agreement with Bio-Cide International, Inc. ("BCI"), Oklahoma, United States. Additionally, Tristel has now been appointed as the distributor for BCI's products throughout the European Union. Tristel had previously been BCI's distributor only in the United Kingdom.

BCI is a manufacturer of a proprietary sodium chlorite solution, which is a key component in Tristel's chlorine dioxide products. BCI has been supplying its sodium chlorite chemistry to Tristel's legionella control and food contamination control subsidiary, Tristel Technologies, for over ten years. The enlarged relationship with BCI signals Tristel's intention to expand its legionella, food and horticulture contamination control business throughout Europe.

BCI is one of three industry partners that form the registration group for sodium chlorite/chlorine dioxide under the European Biocidal Products Directive ("BPD"), which is set to fashion the shape of the biocides industry in Europe. In conjunction with the new supply and distribution agreement, Tristel becomes BCI's representative within the BPD, placing Tristel at the heart of chlorine dioxide's future within the European marketplace.

For further information contact:

Tristel plc

Paul Swinney, Chief Executive

Tel: 01638 721 500

Daniel Stewart & Company Plc

Graham Webster

Tel: 020 7776 6576

Parkgreen Communications Ltd

Tel: 020 7479 7933

Paul McManus

Mob: 07980 541 893

paul.mcmanus@parkgreenmedia.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRILFSERIIIFIT
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.